Vaccines
17 December 2013
Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine17 December 2013
Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes16 December 2013
CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment16 December 2013
Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology16 December 2013
PharmAthene Receives FDA Notification On SparVax®16 December 2013
BIOMAY AG SUCCESSFULLY COMPLETES INTERIM ANALYSIS OF PHASE IIB STUDY WITH THE INNOVATIVE 3rd GENERATION GRASS POLLEN ALLERGY VACCINE BM3212 December 2013
FDA Advisory committee supports approval of Stallergenes’ Oralair® for the treatment of grass pollen allergy11 December 2013
Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer’s Disease10 December 2013
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients6 December 2013
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children5 December 2013
PaxVax Secures $22 Million Series B Financing5 December 2013
Immunicum Reports Positive Phase I/II-Data for the Therapeutic Cancer Vaccine INTUVAX(R) in the Treatment of Kidney Cancer5 December 2013
Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate GEN-004 to Prevent Infections Caused by Pneumococcus3 December 2013
STALLERGENES and ActoGeniX to develop together an innovative new class of oral treatments for allergy3 December 2013
Protectimmun Gets Positive Scientific Advice Response from EMA for Innovative Allergy Prophylaxis3 December 2013
ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement on Development of Pharmaceutical Formulation for IMX10125 November 2013
Celldex Therapeutics’ Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO20 November 2013
Inovio Pharmaceutical’s DNA Vaccine for the Deadly MERS Virus Induces Robust Immune Response in Preclinical TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports